

Improving Outcomes for Patients with Influenza: The Antiviral Agents Every Pharmacist Must Know (Podcast Series)

References:

1. Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States — 2018–2019 influenza season. <https://www.cdc.gov/flu/about/burden/2018-2019.html>. Published January 8, 2020. Accessed February 16, 2020.
2. Centers for Disease Control and Prevention; National Center for Health Statistics. Leading causes of death. <https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm>. Published March 17, 2017. Accessed February 16, 2020.
3. Centers for Disease Control and Prevention. The Pink Book. <https://www.cdc.gov/vaccines/pubs/pinkbook/flu.html>. Published April 15, 2019. Accessed February 16, 2020.
4. Bean B, Moore BM, Sterner B, et al. Survival of influenza viruses on environmental surfaces. *J Infect Dis*. 1982;146(1):47-51.
5. Centers for Disease Control and Prevention. Cold versus flu. <https://www.cdc.gov/flu/symptoms/coldflu.htm>. Published December 30, 2019. Accessed February 16, 2020.
6. Hayward AC, Fragaszy EB, Bermingham A, et al; Flu Watch Group. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. *Lancet Respir Med*. 2014;2(6):445-54.
7. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. *Clin Infect Dis*. 2019;68(6):e1-e47.
8. Centers for Disease Control and Prevention. Guide for considering influenza testing when influenza viruses are circulating in the community. <https://www.cdc.gov/flu/professionals/diagnosis/consider-influenza-testing.htm>. Published March 4, 2019. Accessed February 17, 2020.
9. Shah SC, Rumoro DP, Hallock MM, et al. Clinical predictors for laboratory-confirmed influenza infections: exploring case definitions for influenza-like illness. *Infect Control Hosp Epidemiol*. 2015;36(3):241-8.
10. Tamiflu [package insert]. South San Francisco, CA: Genentech, Inc; 2019.
11. Relenza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018.
12. RapiVab [package insert]. Durham, NC: BioCryst Pharmaceuticals; 2018.
13. Xofluza [package insert]. South San Francisco, CA: Genentech, Inc; 2019.
14. Moscona A. Neuraminidase inhibitors for influenza. *N Engl J Med*. 2005;353(13):1363-73.
15. Hayden FG, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. *N Engl J Med*. 2018;379(10):913-23.
16. Centers for Disease Control and Prevention. Influenza antiviral medications: clinician summary. <https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>. Published January 15, 2020. Accessed February 17, 2020.

17. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ*. 2014;348:g2545.